What Investors Should Know About a $511K Disc Medicine Insider Sale and a 26% Stock Run

The chief legal officer of Disc Medicine sold 6,500 shares of the company for $511,472 on Jan. 2.

The sale represented 14.68% of Khara’s direct holdings, as reported at the time, reducing his direct ownership from 44,293 to 37,793 shares.

This was a derivative-linked transaction, involving the exercise of vested options and immediate sale of the underlying shares, with no indirect entities or trusts involved.

These 10 stocks could mint the next wave of millionaires ›

On Jan. 2, Rahul Khara, the chief legal officer of Disc Medicine (NASDAQ:IRON), exercised and immediately sold 6,500 shares in a derivative transaction valued at approximately $511,472, according to an SEC Form 4 filing.

Transaction value based on SEC Form 4 weighted average purchase price; post-transaction value based on the Jan. 2 market close.

How significant was this transaction relative to Khara’s prior activity?The 6,500-share exercise and sale aligns with the recent median administrative sale size of 7,000 shares, representing 14.7% of direct holdings, which is consistent with the 13.28% median for the past year.

What does the derivative context indicate about insider intent?This transaction was a structured, non-discretionary sale of shares acquired through option exercise, rather than an open-market discretionary sale.

How did this sale affect Khara’s remaining capacity and ownership?Direct holdings declined to 37,793 shares; Khara also reported holding stock options underlying 22,270 shares.

What is the market context for this transaction?The transaction occurred at a weighted average price of $78.69 per share; over the trailing year, Disc Medicine shares delivered a 26.6% return as of the transaction date.

* 1-year price change calculated using Jan. 2, 2026 as the reference date.

Disc Medicine, Inc. develops and advances clinical-stage therapeutic candidates targeting hematologic diseases, with a focus on red blood cell biology, heme biosynthesis, and iron homeostasis.

The company operates a biotechnology business model, investing in research and development to bring novel therapies through clinical trials toward regulatory approval and future commercialization.

Primary customers include healthcare providers and institutions treating patients with serious hematologic disorders, particularly those with unmet medical needs in red blood cell and iron regulation.

Disc Medicine, Inc. is a clinical-stage biotechnology company specializing in innovative treatments for hematologic diseases. Leveraging expertise in red blood cell biology, primarily heme biosynthesis and iron homeostasis, the company is building a portfolio of therapeutic candidates.

This sale came from a pre-scheduled Rule 10b5-1 plan and followed an option exercise, making it an administrative move rather than a discretionary bet against the business. That context matters because Disc is operating from a position of financial strength. The company ended the third quarter with roughly $616 million in cash, cash equivalents, and marketable securities, a balance bolstered by an October public offering that extended its cash runway into 2029. Research and development spending rose meaningfully year over year as Disc advanced multiple programs, including preparations for the potential launch of bitopertin following its NDA submission for erythropoietic protoporphyria. These higher operating costs widened losses to $62.3 million for the quarter, but they also reflect execution rather than distress.

Shares have delivered a roughly 26.6% return over the past year, comfortably ahead of the S&P 500’s roughly 18% gain and suggesting investors are already pricing in pipeline progress. After the sale, the executive retained a sizable equity stake and additional vested options, keeping incentives aligned with long-term outcomes.

Ultimately, administrative insider selling against a backdrop of strong liquidity, advancing clinical programs, and market-beating returns does little to undermine the long-term thesis. The bigger variables remain regulatory execution and clinical data delivery over the next 12 to 24 months.

Derivative transaction: A trade involving financial instruments whose value is based on an underlying asset, such as stock options.Exercised options: The act of using the right to buy company shares at a set price, typically granted to employees.SEC Form 4: A required filing that discloses insider trades of company stock by executives, directors, or large shareholders.Vested options: Stock options that have met required conditions and are now eligible to be exercised by the holder.Direct holdings: Shares owned outright by an individual, not through trusts or other indirect entities.Indirect holdings: Shares owned via trusts, family members, or entities rather than directly by the individual.Non-discretionary sale: A pre-scheduled or automatic sale of shares, not based on the insider’s immediate choice or market timing.Weighted average price: The average price of shares sold, weighted by the number of shares at each price.Clinical-stage: Refers to drug candidates currently being tested in human clinical trials but not yet approved for sale.Hematologic diseases: Disorders related to the blood, such as anemia or clotting conditions.Heme biosynthesis: The biological process by which the body produces heme, a key component of red blood cells.TTM: The 12-month period ending with the most recent quarterly report.

Ever feel like you missed the boat in buying the most successful stocks? Then you’ll want to hear this.

On rare occasions, our expert team of analysts issues a “Double Down” stock recommendation for companies that they think are about to pop. If you’re worried you’ve already missed your chance to invest, now is the best time to buy before it’s too late. And the numbers speak for themselves:

Nvidia: if you invested $1,000 when we doubled down in 2009, you’d have $479,476!*

Apple: if you invested $1,000 when we doubled down in 2008, you’d have $49,342!*

Netflix: if you invested $1,000 when we doubled down in 2004, you’d have $482,451!*

Right now, we’re issuing “Double Down” alerts for three incredible companies, available when you join Stock Advisor, and there may not be another chance like this anytime soon.

See the 3 stocks »

*Stock Advisor returns as of January 5, 2026

Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

What Investors Should Know About a $511K Disc Medicine Insider Sale and a 26% Stock Run was originally published by The Motley Fool